Articles

Results 1 to 5 of 9


Collateralized Fund Obligations (CFOs): The Technicolor Dreamcoat of Fund Finance

USA - September 14 2022 Over the past several years as Collateralized Loan Obligations ("CLOs") reached new and dizzying heights in issuance volume, CFOs have been quietly…

Eric Zeng, David E. Miller, Elliott M. Kieffer, Mary Bear, Christopher P. Duerden, John M. Timperio, Lindsay Trapp

In brief: anticompetitive agreements in the pharmaceutical sector in United Kingdom

United Kingdom - June 30 2020 The essential legal considerations surrounding anticompetitive agreements in the pharmaceutical sector in United Kingdom, including the assessment framework and special issues with vertical agreements.

Alec Burnside, Robert Darwin, Michael I. Okkonen

Snapshot: anticompetitive unilateral conduct in the pharmaceutical sector in United Kingdom

United Kingdom - June 30 2020 A look at key practical considerations surrounding abuse of dominance and other anticompetitive unilateral conduct in the pharmaceutical sector in United Kingdom, including IP rights abuse and pricing conduct.

Alec Burnside, Robert Darwin, Michael I. Okkonen

At a glance: pharmaceutical merger review in United Kingdom

United Kingdom - June 30 2020 This article looks at some of the key legal and practical issues surrounding the competition authorities' review of mergers in the pharmaceutical sector in United Kingdom, including review triggers and thresholds.

Alec Burnside, Robert Darwin, Michael I. Okkonen

Pharmaceutical antitrust law in United Kingdom

United Kingdom - September 6 2019 A structured guide to antitrust law in the pharmaceutical sector in United Kingdom, including the legislative and regulatory framework, merger review, anticompetitive agreements and abuse of dominance.

Alec Burnside, Michael I. Okkonen